-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
65G:F:F- (EUR)
COMMON STOCK | Biotechnology |
Last Closing
USD 0.0798Change
-0.01 (-8.49)%Market Cap
USD 5.98MVolume
350.00Verdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Biotechnology |
Last Closing
USD 0.0798Change
-0.01 (-8.49)%Market Cap
USD 5.98MVolume
350.00Verdict
Verdict
Currency: EUR
Country : Germany
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
NOVA:F | Novo Nordisk A/S |
N/A |
USD 601.26B |
VX1:F | Vertex Pharmaceuticals Incorpo.. |
N/A |
USD 114.63B |
RGO:F | Regeneron Pharmaceuticals Inc |
N/A |
USD 106.63B |
CSJA:F | CSL LTD SPON.ADR 2 |
N/A |
USD 88.75B |
CSJ:F | CSL Limited |
N/A |
USD 88.09B |
0QF:F | Moderna Inc |
N/A |
USD 42.67B |
UNC:F | UCB SA |
N/A |
USD 26.08B |
UNC0:F | UCB S.A. UNSP.ADR 1/2 |
N/A |
USD 26.00B |
1AE:F | Argen-X |
N/A |
USD 24.59B |
1AEA:F | argenx SE |
N/A |
USD 24.49B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
IQQ5:XETRA | iShares MSCI Turkey UCITS.. | 6.30 % | 0.00 % |
N/A |
USD 0.10B |
HTRY:SW | 5.33 % | 0.00 % |
N/A |
N/A | |
TUR | iShares MSCI Turkey ETF | 4.58 % | 0.59 % |
N/A |
USD 0.27B |
FEM | First Trust Emerging Mark.. | 0.00 % | 0.80 % |
N/A |
USD 0.45B |
FEM:LSE | First Trust Emerging Mark.. | 0.00 % | 0.00 % |
N/A |
USD 0.01B |
FEMU:LSE | First Trust Global Funds .. | 0.00 % | 0.00 % |
N/A |
USD 0.01B |
HTRY:LSE | 0.00 % | 0.00 % |
N/A |
N/A | |
IDTK:LSE | iShares MSCI Turkey UCITS | 0.00 % | 0.00 % |
N/A |
USD 0.13B |
ITKY:LSE | iShares II Public Limited.. | 0.00 % | 0.00 % |
N/A |
USD 0.13B |
HTRD:LSE | 0.00 % | 0.00 % |
N/A |
N/A | |
HTR:PA | 0.00 % | 0.00 % |
N/A |
N/A | |
H4ZK:F | 0.00 % | 0.00 % |
N/A |
N/A | |
IQQ5:F | iShares II Public Limited.. | 0.00 % | 0.00 % |
N/A |
USD 0.10B |
H4ZK:XETRA | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -59.80% | 11% | F | 4% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -59.80% | 11% | F | 4% | F | ||
Trailing 12 Months | |||||||
Capital Gain | -73.92% | 11% | F | 5% | F | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -73.92% | 11% | F | 5% | F | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | -20.79% | 19% | F | 7% | C- | ||
Dividend Return | -20.79% | 19% | F | 7% | C- | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 32.04% | 50% | F | 37% | F | ||
Risk Adjusted Return | -64.87% | 21% | F | 10% | F | ||
Market Capitalization | 5.98M | 13% | F | 8% | B- |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total free cash flow in the most recent four quarters.